HORSHAM, PA.—The DIA Pharmacovigilance and Risk Management Strategies 2013 Annual Meeting will be held January 14-16 in Washington, D.C., at the Renaissance Washington D.C. Downtown Hotel, 999 Ninth St. NW. The three-day program will provide expert insight from around the world into the issues and challenges affecting the safety of drug products and biologics through all phases of global product development and implementation.
Discussions from high-level pharmaceutical, biotechnology, and regulatory professionals will focus on new and updated legislation in various ICH regions, the regulatory framework for pharmacovigilance, challenges of implementing risk-assessment and risk-management plans, the impact of social media, and the role of epidemiology in safety analysis.
“Understanding these various aspects that impact product safety is a vital step for industry professionals to assess and manage risk,” said DIA Program Chairperson, Mariette Boerstoel-Streefland. “The program provides essential tools to navigate these challenges within the global scope of drug safety.”
The conference will begin with a keynote address on the history, current state, and future of industry drug safety and risk-assessment delivered by David Goldsmith, MD, President and Senior Consultant at Goldsmith Pharmacovigilance and Systems.
Featured program sessions will include:
- Regulatory Updates From the FDA, presented by Gerald J. Dal Pan, Director of the Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration
- What’s New in Japan – Practicalities of Implementation of Risk Management Plans, moderated by Shinya Yamauchi, Operating Officer at Otsuka Pharmaceutical Co., Japan
- Social Media Panel Discussion, moderated by Elizabeth E. Garrard, Chief Safety OfficerDrug Safety Alliance, Inc., United States
Register here for the Pharmacovigilance and Risk Management Strategies 2013 event. For real-time updates, follow #SAFETY2013 on Twitter.